+919405117673
Gefitinib 250mg Tablets Exporter in India | Cordium Pharmaceuticals Pvt Ltd – Global Supply
Cordium Pharmaceuticals Pvt Ltd is a trusted pharmaceutical exporter from India offering Gefitinib 250mg Tablets, a well-known EGFR Tyrosine Kinase Inhibitor (TKI) used in targeted cancer therapy, especially for non-small cell lung cancer (NSCLC) with EGFR mutation.

We are engaged in the global export and supply support of high-quality pharmaceutical formulations manufactured under strict regulatory compliance standards.

About Gefitinib 250mg Tablets

Gefitinib is an anti-cancer targeted therapy medicine that works by blocking the epidermal growth factor receptor (EGFR), helping to slow or stop the growth of cancer cells.

Usage (General Information)

Gefitinib 250mg Tablets are generally used in:

Non-Small Cell Lung Cancer (NSCLC)
EGFR mutation-positive metastatic lung cancer
Targeted cancer therapy under oncology supervision

Note: This medicine must be used only under prescription and medical supervision.

Dosage Information (General Reference)
Standard adult dose is typically 250 mg once daily
Should be taken at the same time each day
Can be taken with or without food
Dosage may vary based on physician recommendation and patient condition
Possible Side Effects

Like all prescription oncology medicines, Gefitinib may cause side effects such as:

Skin rash or acne-like eruptions
Diarrhea
Nausea or vomiting
Loss of appetite
Liver function changes
Fatigue
Interstitial lung disease (rare but serious)

Medical supervision is required during treatment.

Global Export & Supply Capability

Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical export inquiries and supply coordination to:

United States
Germany
United Kingdom
Netherlands
South Africa
United Arab Emirates
Brazil

We focus on consistent quality standards, documentation support, and global pharmaceutical supply chain solutions.

Contact for Business Inquiry

šŸ“± WhatsApp: +91-9405117673
šŸ“§ Email: info@cordiumpharma.com

For export-related pharmaceutical inquiries, connect with our team for product availability and regulatory support.
Apr 18th, 2026 7:04 PM

Keywords